 Jillian Cotter
Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Community-Acquired Infections | 9 | 2024 | 153 | 4.410 |
Why?
| | Pneumonia | 13 | 2024 | 600 | 3.930 |
Why?
| | Hospitals, Pediatric | 15 | 2025 | 505 | 2.440 |
Why?
| | Anti-Bacterial Agents | 12 | 2025 | 1689 | 1.950 |
Why?
| | Clostridium Infections | 2 | 2024 | 57 | 1.480 |
Why?
| | Respiratory Tract Infections | 5 | 2025 | 372 | 1.220 |
Why?
| | Length of Stay | 7 | 2024 | 1114 | 1.170 |
Why?
| | Feces | 3 | 2023 | 435 | 1.170 |
Why?
| | Child | 41 | 2025 | 20636 | 1.050 |
Why?
| | Communicable Diseases | 3 | 2023 | 145 | 0.940 |
Why?
| | Gastroenteritis | 2 | 2023 | 66 | 0.890 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 285 | 0.870 |
Why?
| | Soft Tissue Infections | 2 | 2021 | 35 | 0.860 |
Why?
| | Multiplex Polymerase Chain Reaction | 2 | 2021 | 51 | 0.860 |
Why?
| | Urinary Tract Infections | 2 | 2024 | 144 | 0.830 |
Why?
| | Diagnostic Tests, Routine | 1 | 2024 | 101 | 0.820 |
Why?
| | Antimicrobial Stewardship | 2 | 2021 | 98 | 0.770 |
Why?
| | Retrospective Studies | 24 | 2025 | 14404 | 0.740 |
Why?
| | Asthma | 4 | 2024 | 2212 | 0.740 |
Why?
| | Pneumonia, Bacterial | 1 | 2022 | 111 | 0.730 |
Why?
| | Cholangitis, Sclerosing | 2 | 2018 | 70 | 0.680 |
Why?
| | Respiratory Insufficiency | 1 | 2024 | 311 | 0.680 |
Why?
| | Dexamethasone | 2 | 2019 | 339 | 0.670 |
Why?
| | Diarrhea | 2 | 2023 | 178 | 0.670 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2019 | 18 | 0.660 |
Why?
| | Infant | 18 | 2025 | 8912 | 0.640 |
Why?
| | Prednisone | 2 | 2019 | 230 | 0.630 |
Why?
| | Hospitalization | 10 | 2025 | 2057 | 0.620 |
Why?
| | Research Design | 1 | 2025 | 1034 | 0.610 |
Why?
| | Administration, Intravenous | 3 | 2024 | 137 | 0.610 |
Why?
| | Liver Function Tests | 2 | 2018 | 107 | 0.600 |
Why?
| | Patient Care | 1 | 2019 | 108 | 0.600 |
Why?
| | Child, Hospitalized | 3 | 2024 | 48 | 0.600 |
Why?
| | Child, Preschool | 15 | 2025 | 10378 | 0.590 |
Why?
| | Gastrointestinal Diseases | 1 | 2020 | 196 | 0.580 |
Why?
| | Pediatricians | 1 | 2019 | 129 | 0.570 |
Why?
| | Humans | 54 | 2025 | 128020 | 0.510 |
Why?
| | Patient Readmission | 5 | 2024 | 663 | 0.500 |
Why?
| | Liver Cirrhosis | 1 | 2018 | 279 | 0.490 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 433 | 0.480 |
Why?
| | Practice Patterns, Physicians' | 2 | 2025 | 1260 | 0.470 |
Why?
| | Propensity Score | 3 | 2024 | 264 | 0.430 |
Why?
| | Administration, Oral | 2 | 2024 | 766 | 0.380 |
Why?
| | Adolescent | 12 | 2025 | 20158 | 0.350 |
Why?
| | Prospective Studies | 8 | 2023 | 7035 | 0.350 |
Why?
| | Emergency Service, Hospital | 8 | 2025 | 1896 | 0.350 |
Why?
| | Cross-Sectional Studies | 8 | 2025 | 5034 | 0.320 |
Why?
| | Intervertebral Disc Degeneration | 2 | 2014 | 33 | 0.320 |
Why?
| | Male | 19 | 2025 | 62758 | 0.300 |
Why?
| | Patient Safety | 2 | 2019 | 286 | 0.260 |
Why?
| | Female | 17 | 2025 | 68017 | 0.260 |
Why?
| | Influenza, Human | 2 | 2023 | 600 | 0.250 |
Why?
| | Amoxicillin | 1 | 2025 | 30 | 0.230 |
Why?
| | Transforming Growth Factor beta3 | 1 | 2014 | 8 | 0.230 |
Why?
| | Diskectomy | 1 | 2014 | 21 | 0.220 |
Why?
| | Thrombocythemia, Essential | 1 | 2014 | 7 | 0.220 |
Why?
| | Tennis | 1 | 2014 | 5 | 0.220 |
Why?
| | Primary Myelofibrosis | 1 | 2014 | 9 | 0.220 |
Why?
| | Polycythemia Vera | 1 | 2014 | 12 | 0.220 |
Why?
| | Ascorbic Acid Deficiency | 1 | 2024 | 7 | 0.220 |
Why?
| | Phlebotomy | 1 | 2024 | 18 | 0.220 |
Why?
| | Scurvy | 1 | 2024 | 14 | 0.220 |
Why?
| | Cannula | 1 | 2024 | 20 | 0.220 |
Why?
| | Intervertebral Disc | 1 | 2014 | 39 | 0.220 |
Why?
| | Cell Survival | 2 | 2014 | 1073 | 0.220 |
Why?
| | Hospitals, Community | 1 | 2024 | 48 | 0.210 |
Why?
| | Treatment Failure | 1 | 2024 | 338 | 0.210 |
Why?
| | Hypertension, Portal | 1 | 2014 | 60 | 0.210 |
Why?
| | Matrix Attachment Region Binding Proteins | 1 | 2013 | 4 | 0.210 |
Why?
| | Critical Pathways | 1 | 2024 | 79 | 0.210 |
Why?
| | Portal Vein | 1 | 2014 | 106 | 0.200 |
Why?
| | Spinal Fractures | 1 | 2014 | 81 | 0.200 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 68 | 0.200 |
Why?
| | Curriculum | 2 | 2019 | 909 | 0.200 |
Why?
| | Low Back Pain | 1 | 2014 | 102 | 0.200 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2024 | 141 | 0.200 |
Why?
| | Seizures, Febrile | 1 | 2022 | 22 | 0.200 |
Why?
| | Viruses | 1 | 2023 | 99 | 0.190 |
Why?
| | Clinical Competence | 2 | 2019 | 1007 | 0.190 |
Why?
| | Treatment Outcome | 5 | 2024 | 10110 | 0.190 |
Why?
| | Lumbar Vertebrae | 1 | 2014 | 230 | 0.190 |
Why?
| | Femur Neck | 1 | 2012 | 59 | 0.190 |
Why?
| | Data Collection | 1 | 2025 | 645 | 0.190 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 119 | 0.190 |
Why?
| | Fever | 1 | 2022 | 295 | 0.180 |
Why?
| | Intracranial Aneurysm | 2 | 2008 | 94 | 0.180 |
Why?
| | Hospital Medicine | 1 | 2022 | 91 | 0.180 |
Why?
| | Virus Diseases | 1 | 2023 | 209 | 0.180 |
Why?
| | Aftercare | 1 | 2022 | 206 | 0.180 |
Why?
| | Pseudomonas Infections | 1 | 2022 | 218 | 0.170 |
Why?
| | Skin Diseases, Infectious | 1 | 2020 | 15 | 0.170 |
Why?
| | Mentoring | 1 | 2022 | 130 | 0.170 |
Why?
| | Endpoint Determination | 1 | 2020 | 75 | 0.170 |
Why?
| | Blood Culture | 1 | 2020 | 20 | 0.170 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 379 | 0.170 |
Why?
| | Severity of Illness Index | 4 | 2022 | 2703 | 0.160 |
Why?
| | Pulmonologists | 1 | 2019 | 15 | 0.160 |
Why?
| | Bone and Bones | 1 | 2012 | 298 | 0.160 |
Why?
| | Symptom Flare Up | 1 | 2019 | 38 | 0.160 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 215 | 0.160 |
Why?
| | Mandatory Reporting | 1 | 2019 | 45 | 0.160 |
Why?
| | Respiration, Artificial | 1 | 2024 | 600 | 0.160 |
Why?
| | Rotator Cuff Injuries | 1 | 2019 | 56 | 0.160 |
Why?
| | Drug Substitution | 1 | 2019 | 51 | 0.160 |
Why?
| | Competency-Based Education | 1 | 2019 | 68 | 0.150 |
Why?
| | Infant, Newborn | 3 | 2024 | 5688 | 0.150 |
Why?
| | Biliary Tract | 1 | 2018 | 15 | 0.150 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2018 | 17 | 0.150 |
Why?
| | Immunocompromised Host | 1 | 2019 | 195 | 0.150 |
Why?
| | Arthroscopy | 1 | 2019 | 205 | 0.150 |
Why?
| | Time-to-Treatment | 1 | 2019 | 178 | 0.140 |
Why?
| | Otitis Media | 1 | 2020 | 160 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 755 | 0.140 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2008 | 1185 | 0.140 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 1020 | 0.140 |
Why?
| | Universities | 1 | 2019 | 399 | 0.130 |
Why?
| | Pandemics | 2 | 2023 | 1473 | 0.130 |
Why?
| | Sepsis | 1 | 2022 | 562 | 0.130 |
Why?
| | Patient Discharge | 1 | 2022 | 850 | 0.130 |
Why?
| | Consensus | 1 | 2019 | 607 | 0.130 |
Why?
| | Preleukemia | 1 | 2015 | 2 | 0.130 |
Why?
| | Incidence | 2 | 2020 | 2614 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 467 | 0.120 |
Why?
| | Colorado | 3 | 2020 | 4369 | 0.120 |
Why?
| | Hospitalists | 1 | 2019 | 231 | 0.120 |
Why?
| | Schools | 1 | 2018 | 436 | 0.120 |
Why?
| | Self Report | 1 | 2019 | 796 | 0.120 |
Why?
| | Quality of Life | 2 | 2023 | 2672 | 0.110 |
Why?
| | Communication | 1 | 2019 | 838 | 0.110 |
Why?
| | Lumbosacral Region | 1 | 2013 | 56 | 0.100 |
Why?
| | Prevalence | 1 | 2020 | 2541 | 0.100 |
Why?
| | Trans-Activators | 1 | 2015 | 381 | 0.100 |
Why?
| | Internship and Residency | 2 | 2019 | 1043 | 0.100 |
Why?
| | Cystic Fibrosis | 1 | 2022 | 1048 | 0.100 |
Why?
| | Intraoperative Complications | 1 | 2013 | 129 | 0.100 |
Why?
| | Medical Errors | 1 | 2013 | 104 | 0.100 |
Why?
| | Gastrointestinal Microbiome | 1 | 2019 | 631 | 0.100 |
Why?
| | Polymorphism, Genetic | 2 | 2013 | 638 | 0.100 |
Why?
| | Age Factors | 1 | 2019 | 3100 | 0.090 |
Why?
| | Spine | 1 | 2013 | 156 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2015 | 632 | 0.090 |
Why?
| | Inflammation | 2 | 2008 | 2646 | 0.090 |
Why?
| | Pediatrics | 1 | 2018 | 1044 | 0.090 |
Why?
| | United States | 5 | 2025 | 13785 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 5353 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2017 | 799 | 0.080 |
Why?
| | Liver | 1 | 2018 | 1826 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 591 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2019 | 2456 | 0.070 |
Why?
| | Primary Health Care | 1 | 2018 | 1639 | 0.070 |
Why?
| | Biomarkers | 1 | 2018 | 3874 | 0.070 |
Why?
| | Disease Progression | 3 | 2019 | 2598 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2008 | 495 | 0.060 |
Why?
| | Aggrecans | 1 | 2014 | 14 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2261 | 0.060 |
Why?
| | Organ Culture Techniques | 1 | 2014 | 145 | 0.050 |
Why?
| | Fracture Healing | 1 | 2014 | 75 | 0.050 |
Why?
| | Proteoglycans | 1 | 2014 | 109 | 0.050 |
Why?
| | Penicillins | 1 | 2023 | 57 | 0.050 |
Why?
| | Uncertainty | 1 | 2024 | 114 | 0.050 |
Why?
| | Ascorbic Acid | 1 | 2024 | 119 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2024 | 348 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 45 | 0.050 |
Why?
| | Bone Development | 1 | 2012 | 49 | 0.050 |
Why?
| | Chromatin Assembly and Disassembly | 1 | 2013 | 101 | 0.050 |
Why?
| | Tensile Strength | 1 | 2012 | 94 | 0.050 |
Why?
| | Cell Polarity | 1 | 2013 | 140 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2024 | 3371 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 130 | 0.050 |
Why?
| | Cattle | 1 | 2014 | 962 | 0.050 |
Why?
| | Goals | 1 | 2022 | 160 | 0.050 |
Why?
| | Cell Lineage | 1 | 2013 | 334 | 0.050 |
Why?
| | Outpatients | 1 | 2024 | 366 | 0.050 |
Why?
| | Social Determinants of Health | 1 | 2024 | 220 | 0.050 |
Why?
| | Cadaver | 1 | 2012 | 306 | 0.040 |
Why?
| | Peer Group | 1 | 2022 | 224 | 0.040 |
Why?
| | Mentors | 1 | 2022 | 178 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 175 | 0.040 |
Why?
| | ROC Curve | 1 | 2022 | 500 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2024 | 500 | 0.040 |
Why?
| | Stress, Mechanical | 1 | 2012 | 460 | 0.040 |
Why?
| | Medicaid | 1 | 2024 | 433 | 0.040 |
Why?
| | Absenteeism | 1 | 2020 | 47 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 518 | 0.040 |
Why?
| | Regression Analysis | 1 | 2012 | 978 | 0.040 |
Why?
| | Pseudomonas aeruginosa | 1 | 2022 | 344 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2023 | 523 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2013 | 569 | 0.040 |
Why?
| | Hospitals | 1 | 2024 | 631 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 759 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2014 | 881 | 0.040 |
Why?
| | Bone Density | 1 | 2012 | 474 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 817 | 0.040 |
Why?
| | Adult | 4 | 2019 | 35177 | 0.040 |
Why?
| | Anti-Infective Agents | 1 | 2020 | 243 | 0.040 |
Why?
| | Bacteremia | 1 | 2020 | 192 | 0.040 |
Why?
| | Shoulder Joint | 1 | 2019 | 163 | 0.040 |
Why?
| | Chronic Disease | 1 | 2023 | 1690 | 0.040 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 361 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2019 | 253 | 0.040 |
Why?
| | Japan | 1 | 2017 | 96 | 0.030 |
Why?
| | Acute Disease | 1 | 2020 | 961 | 0.030 |
Why?
| | Animals | 4 | 2015 | 34487 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 187 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2013 | 1105 | 0.030 |
Why?
| | Internationality | 1 | 2017 | 149 | 0.030 |
Why?
| | Teaching | 1 | 2018 | 210 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2013 | 2757 | 0.030 |
Why?
| | Inpatients | 1 | 2020 | 464 | 0.030 |
Why?
| | Recovery of Function | 1 | 2019 | 630 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 647 | 0.030 |
Why?
| | Blotting, Northern | 1 | 2005 | 198 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2013 | 4006 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2013 | 1896 | 0.030 |
Why?
| | Fatty Acid Desaturases | 1 | 2005 | 32 | 0.030 |
Why?
| | Arabidopsis Proteins | 1 | 2005 | 67 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1266 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1262 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2509 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1194 | 0.030 |
Why?
| | Middle Aged | 3 | 2019 | 30813 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2014 | 3936 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1492 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 940 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1663 | 0.030 |
Why?
| | Mice | 2 | 2015 | 16574 | 0.030 |
Why?
| | Blotting, Western | 1 | 2005 | 1169 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5268 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1934 | 0.020 |
Why?
| | Aged | 2 | 2019 | 21892 | 0.020 |
Why?
| | Neurosurgical Procedures | 1 | 2013 | 170 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2013 | 556 | 0.020 |
Why?
| | Orthopedics | 1 | 2013 | 134 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2012 | 7029 | 0.020 |
Why?
| | Risk | 1 | 2013 | 850 | 0.020 |
Why?
| | Internet | 1 | 2013 | 613 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4853 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2005 | 2669 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3223 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1828 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 88 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 5378 | 0.020 |
Why?
| | Risk Factors | 2 | 2013 | 9696 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2008 | 491 | 0.010 |
Why?
| | Hemodynamics | 1 | 2008 | 1077 | 0.010 |
Why?
| | Sex Factors | 1 | 2008 | 1942 | 0.010 |
Why?
| | Proteins | 1 | 2008 | 933 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2008 | 844 | 0.010 |
Why?
| | Smoking | 1 | 2008 | 1459 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2425 | 0.010 |
Why?
| | Hypertension | 1 | 2008 | 1234 | 0.010 |
Why?
|
|
Cotter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|